Isofol Medical AB AI Stock Analysis
Want to see SE:ISOFOL full AI Analyst Report?
Isofol Medical AB (ISOFOL) AI Stock Analysis
Isofol Medical AB
(Nasdaq OMX AB:ISOFOL)
The overall score of 53 reflects a high-risk, early-stage biotechnology company. The primary strengths are its debt-free balance sheet and significantly improved cash flow management, which provide a stable financial runway. Positive technical trends offer some market support. These are heavily offset by the critical weaknesses of having no revenue, persistent net losses, and a negative P/E ratio, which underscore the company's pre-commercial stage and speculative nature.
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 306.07M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.25M
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- -0.31
- Revenue Growth
- ―
- EPS Growth
- 35.02%
- Country
- Sweden
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Isofol Medical AB Business Overview & Revenue Model
Company Description
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is pre...
How the Company Makes Money
As a clinical-stage biotechnology company, Isofol Medical AB has historically not generated recurring revenue from product sales (no approved commercial products). Its funding has therefore primarily come from external financing rather than operating...
Isofol Medical AB Financial Statement Overview
Summary
The company is pre-revenue with persistent net losses, which is a major weakness. However, the balance sheet is debt-free with a solid equity cushion, and cash flow management has improved dramatically, bringing free cash flow near breakeven. The overall financial health is mixed, balancing a lean, conservative structure against the lack of revenue generation.
Income Statement
5Very NegativeBalance Sheet
65PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 721.00K | 12.80M | 22.41M |
| Gross Profit | 0 | 0 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -57.13M | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -56.63M | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | ||||||
| Total Assets | 118.56M | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 114.83M | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0 | 0 | 0 | 0 | 3.95M | 1.65M |
| Total Liabilities | 23.55M | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 95.01M | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | ||||||
| Free Cash Flow | -700.00K | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -52.63M | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0 | 0 | 0 | 101.00K | 0 | 0 |
| Financing Cash Flow | 101.96M | 84.07M | 0 | 0 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Neutral. The current price of 0.99 is below the 20-day moving average (MA) of 1.21, above the 50-day MA of 0.97, and above the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 6.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ISOFOL.
Isofol Medical AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:ISOFOL53Neutral
SE:ELIC48Neutral
SE:IMMU48Neutral
SE:ONCO44Neutral
SE:BINV37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 360.89M | 1.90 | 63.09% | ― | ― | ― | |
| 53Neutral | SEK 306.07M | -5.28 | -58.68% | ― | ― | 35.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 162.84M | -6.97 | -56.09% | ― | ― | 14.10% | |
| 48Neutral | SEK 217.58M | -1.96 | -19.14% | ― | ― | 13.06% | |
| 44Neutral | SEK 729.43M | -2.60 | ― | ― | 65.37% | 43.28% | |
| 37Underperform | SEK 142.80M | -0.28 | -128.54% | ― | -83.67% | -50.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ISOFOL | Isofol Medical AB | 0.99 | 0.29 | 41.23% | |
| SE:BINV | BioInvent International AB | 2.09 | -27.96 | -93.04% | |
| SE:ONCO | Oncopeptides AB | 1.64 | -3.30 | -66.83% | |
| SE:ELIC | Elicera Therapeutics AB | 2.46 | -2.70 | -52.27% | |
| SE:IMMU | Immunicum AB | 3.50 | -1.49 | -29.79% | |
| SE:CANTA | Cantargia AB | 1.29 | -1.94 | -60.03% |
Isofol Medical AB Corporate Events
Isofol Sets SEK 0.95 Exercise Price for TO2 Warrants
Isofol Medical AB has set the exercise price for 39,863,928 TO2 warrants issued in connection with its June/July 2025 rights issue at SEK 0.95 per share. The price represents 70% of the company’s volume-weighted average share price during 2–13 Novemb...
Isofol Reports Interim Results and Arfolitixorin Study Update
Isofol reported net revenue of kSEK 0 in both the third quarter and January–September 2026. The third-quarter loss was kSEK 11,995, while the nine-month loss reached kSEK 42,785; cash and cash equivalents stood at kSEK 98,087 on September 30.The comp...
Isofol Reports Preliminary Disease Control in Arfolitixorin Trial
Isofol Medical is a clinical-stage biotechnology company focused on cancer treatments. Its drug candidate, arfolitixorin, is a next-generation folate treatment designed to enhance established therapies for solid tumors and is being evaluated in metas...
Isofol Sets AGM 2027 Nomination Committee as Cancer Drug Development Advances
Isofol Medical AB, a Gothenburg-based biotech listed on Nasdaq Stockholm, develops cancer therapies aimed at improving quality of life and prognosis for patients with severe malignancies. Its lead candidate arfolitixorin is designed to boost the effi...
Isofol schedules investor updates to showcase new data on cancer drug arfolitixorin
Isofol Medical will host an Investor & Scientific Update in Stockholm on November 12, followed by a summary meeting in Gothenburg on November 13, to present new data and scientific insights on its lead drug candidate arfolitixorin. The events, featur...
Isofol to Highlight Cancer Drug Candidate at BioStock Investor Meetings
Isofol Medical AB, a Gothenburg-based clinical-stage biotech listed on Nasdaq Stockholm, is developing arfolitixorin, a proprietary next-generation folate treatment intended to enhance the effectiveness of established therapies for solid tumors. The...
Isofol Deepens Arfolitixorin Push as Cash Reserves Bolster Pre-Revenue Pipeline
Isofol Medical AB reported its interim results for January to June 2026, highlighting a continued strategic focus on clinical development rather than commercial revenues. The company remains pre-revenue, posting a first-half loss of kSEK -30,790, but...
Isofol expands arfolitixorin cancer trial to accelerate patient recruitment
Isofol Medical is expanding its phase Ib/II clinical study of arfolitixorin in colorectal cancer by adding new trial sites, including Essen University Hospital in Germany, to accelerate patient recruitment. The move follows regulatory approval of an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
